Clinical research
The investigational drug directs a patient’s own IL-2 toward immune activation while simultaneously preventing IL-2’s immune suppression activities.
It was another busy week for clinical trial news. Here’s a look.
Boston-based Biogen shared data from two Phase III studies at the Clinical Trials on Alzheimer’s Disease conference that showed the latest efficacy data of Aduhelm (aducanumab).
Adaptimmune said that afamitresgene autoleucel (afami-cel) had a significantly positive effect on patients diagnosed with myxoid/round cell liposarcoma (MRCLS) and advanced synovial sarcoma.
As the capabilities have been proven, AI is establishing a firm foothold in the key areas of R&D, drug development, clinical trials, and, to some extent, patient-facing products.
Eisai and Biogen announced positive updates on the Phase IIB 201 and open-label extension studies they are conducting on the use of lecanemab to treat early Alzheimer’s Disease.
AC Immune’s Phase II Lauriet study of investigational anti-Tau monoclonal antibody, semorinemab, in mild-to-moderate Alzheimer’s disease (AD), only met one endpoint.
The drug for treatment-resistant depression reportedly demonstrated significant improvement in patients at its highest dose of 25 mg. Here’s more about it.
The study was momentous in that it was the first head-to-head comparison of two modalities. The Aimovig showed significantly good results and aced primary endpoints.
Sungho Han, Ph.D., founder and CEO of Genuv Inc. in Seoul, South Korea, has built her career and her company by thinking outside the box.
PRESS RELEASES
